Precision is also paramount in terms of getting optimal treatment for people, and the appeal of different treatments might differ amongst people. GLP-1 Treatments Face Hurdles While GLP-1s offer promising benefits for some patients, significant barriers remain regarding supply, cost, and insurance coveragechallenges that Saunders describes as humongous limitations. Novo Nordisks Ozempic and Wegovy have been on the FDAs drug shortage list since 2022
Individual results will vary from clinical trial averages based on multiple factors Lifestyle modifications remain essential for optimal outcomes with any medication Gradual dose increases help minimise side effects during the adjustment period Tracking hormonal markers helps demonstrate PCOS-specific improvements Patience is important as metabolic changes may precede visible weight loss Key Takeaways Retatrutide is a promising triple-agonist medication targeting GLP-1, GIP, and glucagon receptors that may offer superior benefits for women with PCOS compared to current treatments Clinical trials have shown weight loss of approximately 24%, which could significantly improve PCOS symptoms including insulin resistance, menstrual irregularity, and androgen excess The medication is not yet approved in the UK and remains in phase 3 clinical trials, with potential availability in late 2025 or 2026 Current alternatives including Mounjaro and Wegovy are available now and can provide meaningful benefits for PCOS whilst awaiting newer options Combining medication with lifestyle modifications and regular monitoring of hormonal markers offers the best approach for comprehensive PCOS management When to Seek Professional Advice If you suspect you have PCOS or have received a diagnosis and feel your current treatment is inadequate, speaking with a healthcare professional is the appropriate first step
Private Insurance Considerations Some employer benefits plans may cover weight loss medications even before provincial formulary inclusion
Por ejemplo, semaglutida es un agonista simple, que solo activa el receptor GLP-1
For retatrutide, were getting, I think, maximum benefit for a single asset. Kopach anticipates sharing the results of seven Phase III studies by the end of 2026
The realistic timeline: pivotal trial results by mid-2026, NDA submission by late 2026, FDA decision by mid to late 2027, and pharmacy availability by late 2027 or early 2028
